Counseling, Group Therapy Improve Depression, Social Support for Heart Attack Patients
        
        From the corporate.dukehealth.org archives. Content may be out of date.
    
DURHAM, N.C. -- A national trial conducted at eight medical
    centers, including Duke University Medical Center, has
    demonstrated that psychological counseling and group therapy
    significantly improves depression and social isolation for
    patients who have suffered a heart attack.
The findings are important, researchers said, because about
    half of all heart attack victims become depressed, which will
    hinder many from regaining their health. The results of the
    trial, which enrolled 2,481 heart attack patients, were
    published today (June 18, 2003) in the Journal of the American
    Medical Association.
While the trial did not achieve its primary goal of
    demonstrating that cognitive behavioral therapy (CBT) could
    reduce the rates of death or recurrent heart attack after an
    initial heart attack, the researchers believe that the results
    further highlight the importance of treating depression and
    addressing social support issues in this group of patients.
    They also said that while there was no improvement in mortality
    rates, decreasing depression and increasing social support
    improved the quality of life of these patients.
CBT consisted of weekly individual therapy sessions,
    supplemented in some cases with group sessions, aimed at
    helping patients modify their habitual negative thought
    patterns and alter their reactions to stressful situations.
"Although the intervention did not provide a survival
    benefit up to 30 months after the heart attack, it did succeed
    in decreasing depression and increasing social support,
    especially during the first six months," said psychologist
    James Blumenthal, Ph.D., who led the Duke portion of the trial.
    "This demonstrates that patients who are depressed or have low
    social support following a heart attack should be followed, and
    if the symptoms do not clear up, they should be considered for
    treatment.
Dubbed ENRICHD (Enhancing Recovery in Coronary Heart Disease
    Patients), the trial was supported by a $29.6 million grant
    from the National Heart, Lung and Blood Institute. It was the
    first multi-center trial supported by the National Institutes
    of Health to investigate the promise of such behavior therapy
    interventions in patients with heart disease.
One goal of the trial was to enroll a representative
    population of patients, and the researchers believe they
    succeeded, enrolling 1,084 women and 1,397 men and 34 percent
    minorities.
Patients were given standardized tests to determine levels
    of depression and social support within 28 days of being
    admitted to the hospital following their heart attack. Patients
    found to be depressed and/or isolated were then randomized into
    one of two groups: one group received individual counseling and
    group therapy, while the second group received the standard
    cardiac care provided by their personal physicians. Patients
    with higher levels of depression, or who were unresponsive to
    CBT, were also treated with anti-depressant medication.
The psychological tests were repeated six months later and
    then annually.
In terms of the CBT group, scores on standard inventories of
    depression improved 20 percent after six months, while tests of
    social isolation improved 50 percent, when compared to patients
    who did not receive intervention.
Another encouraging aspect of the trial, according to
    Blumenthal, was that this non-pharmacological approach could
    readily be implemented at smaller hospitals as well as the
    large academic centers.
"While eight major medical centers were involved, most of
    the centers had a network of smaller community hospitals within
    their systems where patients were enrolled and treated,"
    Blumenthal said. "This leads us to believe that such cognitive
    behavioral techniques can be successfully delivered in a
    multitude of settings."
Interestingly, the researchers detected a gender difference
    in patients' response to CBT.
"While not statistically significant, there was a trend
    toward men in the CBT condition exhibiting greater reductions
    in mortality and morbidity compared to women," Blumenthal said.
    "More studies are needed to better understand this differential
    response to therapy between men and women."
The results of the trial also suggest the need for
    additional studies to determine the optimal timing and duration
    of psychological interventions and to identify the biological
    and behavioral pathways that link psychosocial health with
    cardiovascular disease.
"We have always been very interested in evaluating
    behavioral, non-pharmacologic approaches to treating
    depression," Blumenthal said. "Because up to one-third of
    depressed patients may not respond to drug therapy, and those
    who do take drugs may complain of side effects, it is important
    to find effective, alternative approaches."
Blumenthal is currently leading a trial to determine whether
    exercise can be an effective treatment for depression in
    middle-aged and older adults. An earlier Duke trial
    demonstrated that supervised exercise was just as effective as
    the most commonly used anti-depression medication in improving
    the symptoms of depression.
The new trial, called SMILE (Standard Medical Intervention
    and Long-term Exercise) is building upon the earlier trial by
    randomizing patients to supervised exercise, exercise at home,
    standard anti-depressant medication or placebo.
Cardiovascular disease is the leading cause of death in the
    United States. It is estimated that about 13 million Americans
    suffer from coronary artery disease. Each year, up to one-third
    of the 1.5 million Americans who suffer heart attacks will die.
    Not only could psychological treatment result in fewer
    hospitalizations and lives saved, it may help reduce the cost
    of treating heart patients with high-tech therapies, now
    estimated at $100 billion a year, Blumenthal said.
Other participating medical centers in the ENRCHD trial were
    the University of Alabama at Birmingham, University of Miami,
    Yale University/Harvard University, Washington University in
    St. Louis, University of Washington in Seattle, Stanford
    University, and Rush-Presbyterian-St. Luke's Medical Center in
    Chicago. The University of North Carolina at Chapel Hill served
    as the Coordinating Center.